Aaron Young, MD
Family Medicine · Elkhart, INNPI 1750504734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,577 and has fallen 50.5% since, to $781 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$862
- AbbVie$830
- Lilly USA, LLC$633
- AstraZeneca$368
- Merck$343
- Boehringer Ingelheim$292
- plus $3K from 42 others
What the payments were for
- Speaking & faculty fees$601%
- Food & beverage$6,01798%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,123 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $135,055 |
| OzempicSemaglutide | 72 | $108,842 |
| TrulicityDulaglutide | 52 | $77,072 |
| MounjaroTirzepatide | 29 | $43,240 |
| EliquisApixaban | 41 | $43,142 |
| FarxigaDapagliflozin Propanediol | 38 | $38,803 |
| WegovySemaglutide | 23 | $35,715 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $20,208 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $19,170 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $15,935 |
| EntrestoSacubitril/Valsartan | 11 | $15,534 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $14,557 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,916 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,411 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $10,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Glyxambi | $292 | $179,604138 claims |
| Novo NordiskOzempic, Wegovy | $862 | $144,55895 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $633 | $120,31281 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $368 | $50,21456 claims |
| PfizerEliquis, Premarin | $248 | $45,56552 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix | $98 | $30,23271 claims |
| MerckJanumet Xr | $343 | $20,20814 claims |
| NovartisEntresto | $241 | $15,53411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $96 | $5,46011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $2,918379 claims |
| AbbVieSynthroid | $830 | $2,62141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Elkhart
- Vikram MehtaElkhart$24K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.